Patagonia Enters into Global Licensing Agreement with Almirall for PAT-001

Patagonia is excited to announce that we have entered into a global licensing agreement with Almirall for our lead product, PAT-001. Almirall and Patagonia Pharmaceuticals will jointly conduct development activities of Patagonia's lead product (PAT-001). Almirall will acquire global commercialization rights for such product and others that could be developed based on existing related Patagonia intellectual property.

For more information, please visit: http://www.almirall.com/en/media/press-releases/media-detail-new?title=almirall-announces-a-global-licensing-agreement-with-patagonia-for-congenital-ichthyosis&articleId=362072